ESG Report

Overview

The report presents Swixx BioPharma's first comprehensive ESG Report, covering 2024 progress across five building blocks. It highlights a company-wide plastic ban, 100% certified waste service providers for warehouses, and a commitment letter to SBTi submitted and accepted. Social achievements include 4,427 rare-disease diagnostic tests, 98 positive reimbursement decisions in CEE, and 100% initial HSE training completion. Governance disclosures include ISO certifications, 10 internal audits, and quarterly whistleblowing reporting to the Board.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Language: English
Pages
File size

Standards

Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

SBTi status

Materiality

Assessment
Basis

Assurance

Statement included

Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services